very the this data. Thanks present you for Thank really exciting Yes. opportunity to much, Sam.
understanding can is what educate so can we put can on X, a if better for in So they vera of the potential Slide I context. have go and XXX this to the polycythemia audience
malignancies neoplasms Well, this a chronic So is hematologic entitled these what cells. of slide Vera? member are patients termed see is cell. increased polycythemia of live you leukemia, as that Polycythemia in frequently stem can the at neoplasms. myeloproliferative these And blood group And production is the of of are a here, several unlike by they mature characterized hematopoietic unusual occur decades. level vera And neoplasms
cell And we'll the the red you've to the destructive that of that's heard and blood production previously patients subsequently. really cells. erythrocytosis vera, polycythemia term increased hear In are the most that's
is age hematocrit, that an occurs sign Now is the the that groups. And vera interesting elevated disease in about of disease. across disease warning and the there This races of States. the polycythemia United which hallmark critical this are XXX,XXX the thing cases is of diagnostic
I over of drug would usage for although XXX,XXX mentioned, of is cases this the prolonged several there's so drug think patients, as the I time. importance decades, live quite of that this period that be these these patients, of
the especially cerebral are acute events. age. in within develop in that cavity. a and called vascular or occur women, about, of incidence abdominal the within talked that arteries we've XX There's as with Budd-Chiari The abdominal veins hepatic that requires life-threatening forms, who primarily they to as thrombosis present life-threatening is, its of individuals the venus, transplantation. and polycythemia thrombosis with incidents years life-threatening who thrombotic incidence occurs women prone strokes, young vein, The There of higher females XX high within in syndrome. severe a however, condition include patients disease the myocardial a events vera the to well The very cavity, it to young particularly infarction, strokes. liver most In are leads thrombotic
of XX group Over shown they've understanding, in new years, the by myeloproliferative tremendous cell that there's be this with neoplasms. understanding characterized blood mutations And last myeloid genes are of been to production. associated been
in of one three the referred due with group erythrocytosis. mutation the elevated severe at exon Most mutation similar thrombotic Virtually the JAKX, of those to is a mutation JAKXVXXXF mutations; smaller commonly, it XX, have a XX So thrombosis driver have polycythemia shorter A is exon for JAKX. is calreticulin occurs in and a hormone patients myeloproliferative they that receptor have and called as XX, patients, are other and MPL, patients with the these hematocrits, and other a gene events a neoplasms vera which again, phenotype, are which the associated increased to thrombopoietin. XX% exon lifespan mutation. and involving
physician vera, and by serendipitously polycythemia of thrombotic potential diagnosis. hematocrit by We're looking an vera The the finding Next and now symptoms initiates slide, role get that a can elevated is the role to going please. so that diagnosis, for of, diagnosis triggered an the PTG-XXX. about event, understanding the you of the talk treatment or polycythemia of of
for myocardial not found be have look and the the prompt, of So JAKXVXXXF within of blood mutation JAKXVXXXF for These hematocrit. the exon could or instance, then an patient that infarction the is acute presence to a tests present. XX present be warning mutation to signs, performed
confirmation sometimes, histopathologic a required examination of marrow And perform diagnosis. the bone to is
are systemic and pruritus. aquagenic symptoms, have severe is disease but water this to exposure or trivial termed unable that pruritus This sweats can complicated stress might seem headache, not only who itchiness. visual that patients symptoms, we've to burdensome but had can occasionally, aquagenic patients symptom also thrombotic succumbed characteristically episodes, by to be a unfortunately lead it's itchiness And fatigue, occurs so shower This like by on suicide. complicated for and night including months has such to
the of polycythemia viscosity or XX%. the reduce Budd-Chiari feature risk the incidence is of events, heart mentioned, events the greatest risk thrombotic number Again, this we essentially attacks, just the the of the reduction the reduced, thrombosis use book red or degree Thrombotic blood include is that I the of vein to embolism blood or that hematocrit deep as of strokes, measure vera. patients to syndrome. and with treatment thrombosis. of stickiness The is that And cardinal thereby erythrocytosis. of hematocrit the is of assures below pulmonary These cells reducing the the and thrombotic
site XXX reductive into this FDA-approved alternative drug for with agents to be systemic treatment are very are questionable leads the not in period polycythemia significant Unfortunately, in phlebotomy are newly XX iron drug is or it Each requiring therapeutic prior years leads that many removal severe of is standard the recommendation first to treated referred the frequent common, exacerbation, require that of or of the which the and contain advanced especially or patients used a tolerability. adverse myelosuppressive -- cells, the that age because or iron is patients diagnosed situation Jakafi phlebotomy. combination could for of is a the attractive with associated And normalization have over with those to therapeutic Again, it product these those phlebotomies with symptoms patients the really those their myelosuppressive a deficiency are phlebotomy agents patients and of red I their that more of that to blood stage hematocrit go have is the and have to supplemental be who that ruxolitinib, an is and or U.S. in drugs, is detail hydroxy or interferon contributing of and So during using the of of it all which phlebotomy, can care used replacement many in of vera. is It previously. only it Jakafi. a at with treat phlebotomy, the interferon, hydroxyurea, thrombosis, can thrombosis, be it I and effects question-and-answer question surrounding agents. which
I've mentioned, shows controlling as evidence, is important to hematocrit events factor the cardiovascular XX% below and that death most Significant the thrombosis. in minimizing thrombosis, due
next the to go let's Please slide.
we're to a bit you when donate blood. phlebotomy, So you about little many which of experienced probably going talk have
receive of to initially. the patients blood unit Phlebotomy the removal most XX%. basically reduce So of is a hematocrit below phlebotomy
an has thrombosis. degree of well maximized. adequate to keep the thrombosis is significantly XX% target with our of demonstrated to that, been that shown in literature is time it's those when always been incidence patients reduces the of So the below of reduced the because be incidence And XX%
may their iron require because have that regular become platelets -- of poor would symptoms. or their may further these augmentation antithrombogenesis phlebotomies the heart is or deficiency a the stays of augment results vera. to polycythemia in failure Furthermore, major And going infusions or low-dose -- aspirin their feeling a undergo patients debilitating phlebotomy dizzy because -- report often tired facility addition, or to iron patients patients require elderly, long Patients fluid makes in phlebotomy. paralyze these and in especially receive congestive have deficiency -- outpatient who of hypertensive, with the Many debilitating after balance. factor. will this this In our that in fluid that
impairments. patients and is because weakness of impairment big really jobs. deal cognitive fatigue, fuzzy cognitive This of do severe particularly the concentrate having mentioned, a cannot and complain they a I brain many and their As syndrome,
thrombotic some restless addition, patients them an of a craving for year in hydroxyurea have And clay, from and ice patients phlebotomies unusual is substances events. which going a inferior termed with as more incidence a Three in the In those receiving of which the is patients some sleep. prognosis higher of pica. or syndrome, such prevents associated or unfortunately, then, leg have to
think also hydroxyurea, in could receiving frequent situation, phlebotomies who these even that can in patient their improve eliminate further regimen you those those, is for that XXX combination therapy patients. So a the with in and treatment
way But I a elevated intervals. X-month the X- the think and at reality, of most they X-month X- real of part or have you'll during to about that that's important visits, likely periods see no our have are say, high-quality significant that we hematocrit At their that monitor visit it patients, let's this phlebotomy. their hematocrit we aspect the it's elevated that and time of drug these an triggers they that have in an interval, us amount see only we see the or that of a for them clinic. detected between to to interval time, do is
hematocrit as about So that or phlebotomy or really PTG-XXX there's is agents really with other a to the control, the sustained we've able of cool any part with been but, never alone. achieve which see, you'll
Let's hormone number on of action. go its non-cytoreductive and mechanism hepcidin now to is which XX, PTG-XXX mimetic, Slide
iron Well, blood hepcidin the promoting is and production how couple recently primary So playing decreasing in role of of macrophages and a this been drug decades, availability the hormone, really established last has the cells. does red iron work? sequestration in for of
in additional to tissues. alter, type nursing termed is marrow present the iron macrophages not but blood are blood red in are produce feed because marrow So essentially cells. to cell, the allow also in to them the activity macrophages are to their red cells marrow, to they're in and of bone they all cells body present But white only a the and other
to JAKX the disregulated is process by erythrocytosis. leading mutation This
excess erythroid by red in believed the production that Therefore, macrophages. transfer to iron its to PTG-XXX limit polycythemia cells essentially So the is preventing in allowing remain precursors. vera into the
blocks associated the that addition, symptoms of the the systemic marrow. in And iron therefore, the believe we in are the present that's macrophages many In vera. it polycythemia alleviates of with outside tissues
to go been really now in XX, study a the on Slide II This which is Let's is Phase interesting constructed. manner has this which design. study
meet an where patients X to are days. over components X weeks we there is the believe one to the randomized I'm is see essentially weeks. to extension to those as XX%, have phase, which effective dose-finding dose hematocrits patients to dose-escalate able sure can dose, about for the XX where will we go to be You hematocrit that two allowed then them, the phase is XX then the Part where XX-week phlebotomies. will And withdrawal If where receive be up are evaluation receive dose-finding there there's fixed a I open-label inadequate requirements. to XX%. placebo that, maintain part period, supplemental put a on will patient's that active again placebo, are that. Then dose they period to essentially get exceed efficacy happy to be allow XXX. will we And on either them or to up patient's the XX XX- then below they a they And the patients phases. blinded
triangles least And each been you the solid weeks these of This the that criteria, responses that's entry the seen Let's evaluated. go the is number XX see period. and three on that phlebotomies that left can in phlebotomies, had line. the Slide prior and see these seven that them you have patients, treatment. been indicate can lot were patients to during And at of to red of we've described, the have that to a The essentially XX.
to dotted the thing time to And was and red then is one at patients lot unfortunately, the triangles of that's and that the, which due right, our started. that's first are left the line, the And and there of doses, pandemic. this drug strikes the only red the you one that to who a dose to triangle the can missed due one you see
time. of numbers the And over that period were administered doses that indicate the
escalation you So in and slide. discuss see for de-escalation, a XXXXXX, instance, the there on patient dose then I'll which can was subsequent
administration is this really this most careful important that this So that probably and drug phlebotomy slide really, basically and is with almost shows summarizes our And virtually slide. of the eliminated. it titration
Next slide.
milligrams. is missed line. blue this One patient, patients. And is COVID dose two that the individual was milligrams, infection. see is the the you was that on because infection. then who XX XX milligrams, time he can focus started of can at he a unable And had COVID XX he at Let's because And this to that patient, top the went which the the in on come to you XX.X, of hematocrit see up
and a kept and it dose he his So hematocrit XX. in, would we was we've have XX. but milligrams, and did now on to XX his phlebotomized you dropped, phlebotomy Wednesday, on He above not milligrams, XX increased his seen below him came still and require was we him, hematocrit
was can If can you XX, at remained XX remains and look of started week and you time, and was, on in phlebotomy-free. that XX. on We hematocrit you red, milligrams. hematocrit then that got XX over period got see that, then bottom at And week is that bright below patient then XX dropping time she on to again that to of dose on XX.X. X Wednesday, who and XX XX milligrams We cut the to has she you saw milligrams, that, see a can seven to led our increased her patient see
to below can time, over of remained see XX.X. We you see led milligrams, dropping of dose got at week hematocrit hematocrit and And look period time can at Wednesday, on milligrams. to XX on We milligrams bright her patient you has saw then XX, that you our and XX to zero patient red, bottom that, who on remains on is cut X week -- was that she XX that, then phlebotomy-free. again in that XX. XX see got If was the XX she to you that a then started can and increased and
home that empowering lot can at the and you to there's them being The freedom disease. giving drugs dose easily are adjustment patients, administered also own do. their So by of them a a control
that Slide XX, to an that do that here ferritin the iron-deficient. doses, see see And And you we you in it If is storage indicates really its where over reflects bottom of extremely at line And hitting we're if And the patient we these can the numbers recall, the column, is ferritin these that administration you control This PTG-XXX one what you're received molecule drug can of in addresses time, doses know XX. each is except serum iron. go is can subsequent ferritin. below with of with how a the extremely target. a ferritin levels low increased vertical XXX. and hematocrit patients dose the an measuring if
So drug the data that acting target. these indicate on is
but we had recorded the is you serious one were see XX-milligram just about sample Because adverse defense? essentially were a can injection set and resolved no must at This bruise What patients of that small events and irritations, decades. that at chronic the patients adverse events the disease, slowly treated over is a essentially site a one dose. had adverse a that this the will anticipate that be
go XX, on Page which our to Let's now summary. is
start this off. to just So
about perhaps for used at the of XXX that optimal is in great I which what there's of XXs, -- think has used since acute great hormone patients, phlebotomy years. the There's leukemia. almost debate being chemotherapy been never disease. field, this a evolution to in is is be been myeloid therapy been for might really these this concern type for incidence And least, from agent. myelosuppressive increasing about anticipated We I've probably used used the
this paradigm trial a it and great I think patients importance represents shift represents vera. polycythemia with So for has really -- this really
associated All have patients we avoid that of vera. think sustained control of lead of as control additional bottoming I to systemic tried attack cardiovascular their events the you that So most and levels, Persistent their really levels potential are -- anticipate hematocrit and treatment as can stroke. indicate the This this hematocrit, without toxicities need will the the you. that the is thrombotic are down entirely dose elimination that's compliant with phlebotomy and easily with heart we offers again, drug drug to or the almost important a also phlebotomy of were symptoms of the of of significant I up associated to And I alleviation to of excursions for I demonstrates patients therapy sustained these think any of discussed conclude possibility data in the such episodes. which issues with phlebotomy-free. administration therapy elevated weekly one polycythemia inherent the hematocrit
in Also, available know iron phlebotomy this related reduction sufficient deficiency. are to we may avoid symptoms that allow that to be systemically to iron
prior This as has is studies. first PV. PTG-XXX non-cytoreductive So in results the and well safety for therapy the potential drug tolerated has a profile with similar
this about its see So your Thank presentation, drug and I'm you my future. enthusiastic for as from time. you extremely can
